Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Mantle-Cell 6Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, B-Cell 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Lymphoma 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 31fludarabine 28Whole-Body Irradiation 18Mycophenolic Acid 18venetoclax 14Tacrolimus 14fludarabine phosphate 13Standard of Care 13Specimen Handling 10Practice Guidelines as Topic 10Melphalan 10Busulfan 10Sirolimus 9Thiotepa 8Interviews as Topic 8Azacitidine 8Educational Status 7trametinib 6Surveys and Questionnaires 6Methods 6Mesna 6Biopsy 6thymoglobulin 5Rituximab 5Magnetic Resonance Spectroscopy 5Filgrastim 5Early Intervention, Educational 5Behavior Therapy 5Antilymphocyte Serum 5Peripheral Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × brexucabtagene autoleucel × 1 year × Clear all
NCT05041309 2026-05-14

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Gilead Sciences

Enrolling by invitation
1,000 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡